CO2017002356A2 - Métodos para tratar la depresión usando moduladores de nmda - Google Patents

Métodos para tratar la depresión usando moduladores de nmda

Info

Publication number
CO2017002356A2
CO2017002356A2 CONC2017/0002356A CO2017002356A CO2017002356A2 CO 2017002356 A2 CO2017002356 A2 CO 2017002356A2 CO 2017002356 A CO2017002356 A CO 2017002356A CO 2017002356 A2 CO2017002356 A2 CO 2017002356A2
Authority
CO
Colombia
Prior art keywords
methods
treating depression
nmda modulators
nmda
modulators
Prior art date
Application number
CONC2017/0002356A
Other languages
English (en)
Spanish (es)
Inventor
Ron Burch
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of CO2017002356A2 publication Critical patent/CO2017002356A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2017/0002356A 2014-08-14 2017-03-10 Métodos para tratar la depresión usando moduladores de nmda CO2017002356A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462037374P 2014-08-14 2014-08-14
PCT/US2015/045071 WO2016025721A1 (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Publications (1)

Publication Number Publication Date
CO2017002356A2 true CO2017002356A2 (es) 2017-06-09

Family

ID=55304631

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0002356A CO2017002356A2 (es) 2014-08-14 2017-03-10 Métodos para tratar la depresión usando moduladores de nmda

Country Status (18)

Country Link
US (1) US20170296616A1 (enExample)
EP (1) EP3180015A4 (enExample)
JP (2) JP2017524721A (enExample)
KR (1) KR20170040351A (enExample)
CN (1) CN106659763A (enExample)
AU (2) AU2015301650A1 (enExample)
BR (1) BR112017002930A2 (enExample)
CA (1) CA2957937A1 (enExample)
CL (1) CL2017000378A1 (enExample)
CO (1) CO2017002356A2 (enExample)
IL (1) IL250557A0 (enExample)
MX (1) MX2017002052A (enExample)
PH (1) PH12017500275A1 (enExample)
RU (1) RU2017107033A (enExample)
SG (2) SG10201810016XA (enExample)
UA (1) UA123623C2 (enExample)
WO (1) WO2016025721A1 (enExample)
ZA (1) ZA201701526B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
EP3706734A1 (en) * 2017-11-10 2020-09-16 Naurex Inc. Methods of administration of nmda receptor agonists
US20200368310A1 (en) * 2017-12-05 2020-11-26 Naurex, INC Treatment with nmda receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
EP2485751B1 (en) * 2009-10-05 2014-05-21 Northwestern University GLYX-13 for use in a method of treating refractory depression
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans

Also Published As

Publication number Publication date
BR112017002930A2 (pt) 2017-12-05
CL2017000378A1 (es) 2017-11-03
SG10201810016XA (en) 2018-12-28
MX2017002052A (es) 2018-08-15
EP3180015A4 (en) 2018-02-14
JP2020128391A (ja) 2020-08-27
IL250557A0 (en) 2017-03-30
AU2015301650A1 (en) 2017-03-23
PH12017500275A1 (en) 2017-07-03
ZA201701526B (en) 2018-05-30
EP3180015A1 (en) 2017-06-21
JP2017524721A (ja) 2017-08-31
UA123623C2 (uk) 2021-05-05
SG11201701134XA (en) 2017-03-30
RU2017107033A3 (enExample) 2019-02-12
KR20170040351A (ko) 2017-04-12
US20170296616A1 (en) 2017-10-19
CA2957937A1 (en) 2016-02-18
RU2017107033A (ru) 2018-09-14
AU2020203165A1 (en) 2020-06-04
WO2016025721A1 (en) 2016-02-18
CN106659763A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
MX2016012880A (es) Cadena j modificada.
MX389663B (es) Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
MX2016012781A (es) Anticuerpos anti-ox40 y metodos de uso.
EP3679908C0 (en) OCULAR IMPLANT DELIVERY DEVICE
SG10201900574SA (en) Virtual currency conversion device, method and computer program
PT3107607T (pt) Módulo led para dispositivos geradores de aerossóis, dispositivo gerador de aerossóis com um módulo led e método para iluminar vapor
IL243707A0 (en) Treatment to regulate the microbiota in the intestine
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112017027721A2 (pt) formulação de alta concentração
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
BR112017004745A2 (pt) adição a um aplicador médico
TW201613587A (en) Medical treatments based on anamorelin
MX2017012553A (es) Compuestos espirociclicos.
CL2016002754A1 (es) Dispositivo de tratamiento y procedimiento de tratamiento para el decapado y fosfatado de piezas de metal
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
BR112017008097A2 (pt) método para tratar condições oculares